The inactivation of certain tumor suppressor genes is thought to play an important role in the genesis of a number of tumor types. For example, inactivation of the Retinoblastoma (Rb) tumor suppressor is frequently observed in a proportion of sporadic human breast cancers. While these studies suggest that inactivation of key tumor suppressor genes may play an important role in the induction of mammary cancers, direct evidence supporting this contention is lacking. Because polyomavirus (PyV) Large T (LT) antigen is known to associate with and inactivate certain members of the Rb family (p105Rb, p107, p130), we have derived transgenic mice which express PyV LT antigen in the mammary epithelium. As expected mammary epithelial-speci®c expression of PyV LT antigen resulted in the induction of mammary tumors which correlated with their capacity to associate with Rb family members. In addition to mammary carcinomas, female transgenic mice expressing the PyV LT transgene frequently develop uterine leiomyomas. Because loss of heterozygosity involving the human CUTL1 (Cut like 1) gene located at chromosomal position 7q22 has been recently implicated in sporadic human uterine leiomyomas, we tested the hypothesis that PyV LT antigen may also form speci®c complexes with CUTL1. The results of these analyses revealed that speci®c complexes of CUTL1 and PyV LT antigen could be detected in both leiomyomas and mammary tumors. Taken together, these observations suggest that PyV LT antigen may be involved in inducing these tumors by sequestering both CUTL1 and Rb growth regulatory proteins.
Introduction
Genetic and biochemical analyses of DNA tumor viruses have demonstrated that the products of the early regions play a pivotal role in inducing cellular transformation. For example the large (LT), middle (MT) and small (ST) tumor antigens of Polyomavirus (PyV) are the principle viral oncoproteins involved PyV-mediated cellular transformation. Recent studies suggest that viral oncoproteins induce cellular transformation through similar mechanism. For example, the Papillomavirus E7 protein, SV40 Large T antigen, Adenovirus early protein E1A and PyV Large T (LT) have all been shown to complex members of the Rb family (Dyson et al., 1990) . This family currently comprises the product of the retinoblastoma susceptibility gene (Rb, p105), p107 and p130 (Whyte, 1995) . While the precise molecular mechanism through which Rb family members function remains uncertain, they are thought to regulate entry in various stages of the cell cycle (Whyte, 1995) . Thus, the capability of attenuating the function of these cell cycle control genes within an infected cell lends a selective growth advantage to the virus by inducing entry into the cell cycle.
The Rb gene product has gained signi®cant attention over the past few years as the prototype tumor suppressor gene. Initially, constitutional homozygous deletion of this gene within retinoblasts was blamed as the causative factor in childhood retinoblastoma (Whyte, 1995) . In addition, Rb mutations have been observed in several other cancers including osteosarcomas, small cell carcinomas of the lung, bladder cancer cell lines, and breast carcinomas (Marshall, 1991) . Several independent groups have also reported Rb mutations in 7 ± 19% of primary breast tumors (T'ang et al., 1988; Varley et al., 1989) . Moreover, these studies revealed 29% of breast tumors failed to demonstrate the presence of Rb by immunohistochemical analyses (Tang et al., 1988; Varley et al., 1989) . Despite the correlative evidence implicating Rb involvement in breast cancer, there is relatively little known concerning the role Rb plays in mammary tumorigenesis. Several studies have shown that mammary epithelial-speci®c expression of the Simian Virus 40 (SV40) large T (LT) antigen which is known to sequester members of the Rb family leads to the induction of focal mammary tumors which appear after a long latency period (Choi et al., 1988; Shibata et al., 1996; Li et al., 1996) . However, because SV40 LT antigen is also known to complex with the p53 tumor suppressor product the relative contribution of inactivation of the Rb to the tumor phenotype observed in these strains is unclear.
In addition to its ability to induce mammary tumors, expression of SV40 large T in transgenic mice under transcriptional control of smooth muscle promoter has been reported to result in the induction of leiomyomas (Romagnolo et al., 1996) . Whereas loss of function mutations involving the Rb gene have not been reported in sporadic leiomyomas, speci®c deletion of chromosome 7q22 has been frequently observed in human leiomyomas (Ozisik et al., 1996; Sargent et al., 1996) . More recently, this region has been narrowed to region encoding the homeobox domain containing protein known as CUTL1 (Lemieux et al., 1994; Zeng et al., 1997) . Interestingly, the human CUTL1 product has been demonstrated to bind the promoter region of the c-myc proto-oncogene and repress c-myc expression . However, whether the ability of SV40 LT antigen to induce leiomyomas in transgenic mice is related to its in¯uence on CUTL1 function is unclear.
To directly assess the importance of the Rb tumor suppressor family in mammary tumorigenesis, we have generated four transgenic mouse strains expressing a cDNA encoding the PyV LT antigen under transcriptional control of the mouse mammary tumor virus (MMTV) promotor/enhancer. Unlike SV40 LT antigen, mammary epithelial expression of PyV LT antigen should not aect p53 tumor suppressor function but rather speci®cally reduce the functional levels of Rb in the mammary gland (Larose et al., 1991; Dyson et al., 1990) . Although mammary epithelial-speci®c expression of the PyV LT strains was not initially associated with any apparent phenotype, older female transgenic mice developed focal mammary tumors. In addition to the mammary tumor phenotype, many of the male and female transgenic mice developed a number of reproductive tract abnormalities including testicular and uterine leiomyoma tumors. Given the potential involvement of CUTL1 in uterine leiomyomas, we examined whether the expression of CUTL1 was altered in both PyV LT induced leiomyomas and mammary tumors. The results of these analyses revealed that the levels of CUTL1 were elevated in both classes of tumor tissues compared to adjacent normal tissue. Signi®cantly, the elevated levels of CUTL1 in these tumors was further correlated with the formation of speci®c complexes between the cellular CUTL1 protein and PyV LT antigen. These observations raise the intriguing possibility that sequestration of key cell cycle regulators such as CUTL1 and Rb family members by PyV LT antigen is involved in the induction of both mammary and uterine tumors.
Results

Transgenic mice expressing the PyV LT antigen in a variety of tissues develop multiple tumor types
To assess the potential role of Rb family members in mammary tumorigenesis, we have taken advantage of the ability of certain viral gene products to associate with and inactivate Rb family members. Unlike SV40 LT antigen which is known to couple with both Rb family members and the p53 tumor suppressor products, PyV LT antigen is known to associate only with the members of the Rb family (Dyson et al., 1990; Larose et al., 1991) . To direct the expression of the PyV LT product to the mammary epithelium, we derived transgenic mice carrying the cDNA encoding PyV LT antigen under the transcriptional control of the MMTV LTR (Figure 1a) . Microinjection of the MMTV/PyV LT cDNA expression cassette into one cell mouse zygotes resulted in the generation of four independent transgenic strains (LTN1-4). To assess the tissue speci®city of transgene expression for each of these strains total RNA isolated from a variety of organs was subjected to RNase protection analyses using an antisense riboprobe speci®c for the noncoding SV40 polyadenylation signals (Figure 1a , SPA). Representative results from these analyses for the LTN-1 transgenic strain are shown in Figure 1b . As expected, transcripts corresponding to the transgene were detected in the lactating mammary glands from female transgene carriers (Figure 1b , lane 11 and 13). However, transgene expression could not be detected in virgin mammary glands (Figure 1b, lane 12) . In addition to the observed mammary gland expression, transgene transcripts were detected in salivary glands, thymus, spleen, uterus, lung, brain and ovaries and the male testes and seminal vesicles (Figure 1b) . Consistent with these observations, RNase protection analyses of the tissues from another independent strain (LTN-4) exhibited a similar pattern of tissue speci®c transgene expression (Table 1) . However, transgene expression could not be detected in any tissue RNA samples derived from the LTN-2 line (Table 1) .
Although mammary epithelial-speci®c expression of PyV LT antigen was not initially associated with any obvious phenotype, older female animals eventually developed mammary tumors. The incidence of mammary tumor formation appears to directly correlated with both age and parity of female transgenic carriers. Indeed, of the virgin animals analysed for tumor formation, only 6.6% (4/61) developed mammary carcinomas, whereas 23.8% of multiparous animals (5/23) of the same strain developed mammary tumors. Histological analyses of these mammary tumors revealed the presence of focal secretary adenomatous carcinomas which arise adjacent to morphologically normal epithelium (Figure 2a ). Because these tumors arose next to morphologically normal mammary epithelium and occurred after a long latency period (T50=449 days, Table 1 ), expression of PyV LT antigen is not sucient for mammary tumor progression.
Despite the relatively poor transforming properties of PyV LT antigen in the mammary gland, other tissues expressing the PyV LT transgene are more susceptible to the transforming activity of PyV LT antigen. In particular, female transgenic mice derived from three independent founder strains frequently developed benign uterine leiomyomas whereas male transgenic mice frequently developed testicular tumors. Histological examination of these leiomyomas revealed that they were composed of whorling bundles of smooth muscle which bore a remarkable resemblance to human leiomyomas (Figure 2b ). The penetrance of the leiomyoma phenotype appeared to somewhat dependent on parity status since 50% of virgin animals developed leiomyoma (n=61) whereas only 24% of the multiparous animals were detected with leiomyoma tumors (n=23). Indeed, other groups have reported that the induction of leiomyoma in other transgenic strains may be in¯uenced by estrogen levels (Romagnolo et al., 1996) .
In addition, to the occurrence of these benign uterine lesions, expression of the PyV LT transgene in the male reproductive tract was associated with growth disturbances involving the seminal vesicles and testes. Testes-speci®c expression of the PyV LT transgene was associated the formation of testicular tumors. Although the testicular tumor phenotype occurs with 100% penetrance, they arise only after long latency suggesting the involvement of additional genetic events. The testes tumors were comprised of sheets of small round cells with eosinophilic cytoplasm which are interstial in origin (Leydig cells) (Figure 2c ).
To determine whether the levels of PyV LT protein were altered during tumor progression in these strains, protein extracts from various tumor and adjacent normal tissues was analysed by immunoblot analysis using PyV LT-speci®c antisera. The results revealed that in each case, the tumor tissues possessed elevated levels of PyV LT protein compared to the adjacent normal tissues (Figure 3 ). These observations suggest that induction of mammary, testicular and uterine tumors are associated with elevated levels of PyV LT antigen. Taken together, these observations suggest that elevated expression of PyV LT transgene can induce growth disturbances in variety of dierent tissue types. The transforming properties of PyV LT antigen correlate with its capacity to associate with members of the Rb family and the murine CUTL1 protein
Because the immortalizing properties of PyV LT antigen is thought to involve its capacity to complex with and inactivate members of the Rb family (Pilon et al., 1996; Larose et al., 1991) , we assessed whether speci®c Rb family members were associated with PyV LT antigen. To accomplish this, mammary tumor lysates from PyV LT or control MMTV/neu transgenic mice (Guy et al., 1992) were subjected immunoprecipitation/immunoblot analyses with antibodies speci®c to the Rb, p107 and p130 and PyV LT antigen ( Figure  4 ). The results revealed that all three Rb family members could be coimmunoprecipitated with PyV LT antigen ( Figure 4 , lanes 1, 3, 5). In contrast, coimmunoprecipitation analyses of control tumor lysates derived from the MMTV/neu mice failed to reveal a comparable association ( Figure 4 , lanes 2, 4, 6). These observations suggest that Rb family members are sequestered in complexes with PyV LT antigen in these mammary tumors. Given the correlation between loss of heterozygosity of the CUTL1 locus and the induction of leiomyoma in human clinical specimens (Zeng et al., 1997; Lemieux et al., 1994) , we decided to investigate whether the levels of CUTL1 protein were reduced in these leiomyoma and mammary tumor samples. To accomplish this immunoprecipitation/immunoblot analyses with antibodies speci®c for murine CUTL1 was performed on a variety of tumor lysates ( Figure 5 , lower panel). In contrast to our expectation, the results revealed that the CUTL1 protein levels were elevated in mammary and leimyoma tumors derived from the PyV LT transgenic mice ( Figure 5 , lower panel, lanes 4, 5). However, because tumor lysates derived from the Neu-induced mammary tumors failed to exhibit signi®cant levels of CUTL1 protein ( Figure 5 , lower panel, lane 1), the elevated levels of CUTL1 observed in the mammary tumors and the leiomyomas does not appear to re¯ect a general feature of oncogenic transformation.
Given the potential involvement of CUTL1 as a tumor suppressor in human leiomyomas it is conceivable that the elevated levels of CUTL1 observed in these tumor tissues is due to its interaction with PyV LT antigen. Indeed, the interaction of SV40 LT antigen with the p53 tumor suppressor results in stabilization of p53 protein levels (Reich et al., 1983) . To explore this possibility, co-immunprecipitation analyses with both CUTL1 and PyV LT antisera was performed on protein extracts derived from either tumor (breast tumor-BT or leiomyoma-LEIO) or adjacent tumor tissues. Immunoprecipitation with antisera speci®c for murine CUTL1 followed by immunoblotting for PyV LT revealed the presence of co-precipitating PyV LT in leiomyomas and mammary tumors (Figure 5, upper panel, lanes 4, 5) . The observed interaction between CUTL1 PyV LT appears to be speci®c since tumor extracts from leiomyomas or mammary tumors were immunoprecipitated with a non-speci®c antibody (Neu monoclonal) or no antibody revealed no evidence of PyV LT protein ( Figure 5 , lanes 3, 7 and 2, 6 respectively).
To further explore the relationship between the association of CUTL1 and PyV LT antigen in tumor progression, we assessed whether the formation of CUTL1/PyV LT complexes was correlated with induction of the various tumor types exhibited by these MMTV/PyV LT mice. To accomplish this, protein extracts derived from both matched normal and tumor tissues were immunoprecipitated with CUTL1 antibodies and the immunoprecipitates subjected to immunoblot analyses with either CUTL1 or PyV LT-speci®c antibodies (Figure 6a and b) . The results showed that in mammary tumors elevated levels of CUTL1 could be detected in the tumor tissues compared to normal tissue counterparts (Figure 6a , compare lane 5 to 6). A less dramatic elevation of CUTL1 levels was observed in the leiomyomas compared to their normal tissue counterparts ( Figure  6a, lanes 1 and 2) . The elevated CUTL1 levels in both instances was further correlated with induction of speci®c complexes with CUTL1 and PyV LT antigen ( Figure 6b , lanes 2 and 6). By contrast to these observations, a similar set of analyses failed to show either elevated levels of CUTL1 or speci®c CUTL1/ PyV LT complexes in either normal testicles or testicular tumors even after extended exposure times (Figure 6a , lanes 3 and 4 and Figure 6b , lanes 5 and 6). The dierence in the ability of CUTL1 to associate with testicular tumor extracts was not due changes in the levels of PyV LT since comparable levels of PyV LT protein can detect the testicular tumors and leiomyomas and normal mammary gland (Figure 6c compare lane 4 to lanes 2 and 5). Indeed, in both these latter cases CUTL/PyV LT complexes can be readily detected (Figure 6b, lanes 2 and 5) . These data argue that the formation of CUTL1/PyV LT complex is tissue restricted. Taken together, these observations suggest that the formation of speci®c complexes of PyV LT and CUTL1 may be involved in the induction of both mammary tumors and leiomyomas.
To assess whether formation of PyV LT and CUTL1 complexes could in¯uence the DNA binding properties of the CUTL1, we performed electrophoretic shift assays (ESMA) with tissue extracts from both wild type or tumor tissue extracts from either FVB or LT transgenic animals on oligonucleotide containing a CUTL1 consensus binding site. To con®rm that observed shifts were due to CUTL1 binding, the binding reactions were incubated either without Antibodies (No Ab) or antibodies speci®c to either CUTL1 (Anti-Cut) or nonspeci®c hemaglutinin (Anti-HA). Previous studies have demonstrated that incubation of anti-CUTL1 antibodies can eectively disrupt CUTL1 DNA complexes (A Nepveu, personal communication). As shown in Figure 7 , these analyses revealed that CUTL1 protein derived from either non transgenic uterus (FVB Uterus, lanes 1 ± 3) or PyV LT induced Leiomyomas (Leio, lanes 3 ± 12) was capable of shifting the CUTL1 binding site alone or in the presence of a nonspeci®c antibody (Anti-HA). However, incubation of the binding reactions with CUT1 speci®c antisera eectively interfered with CUTL1-DNA complexes ( Figure 7 , lanes 2, 5, 8, 11). Similar results were also obtained with tissue extracts from the mammary epithelium (Figure 7 , FVB Lact., lanes 13 ± 15) or PyV LT induced mammary tumors (Figure 7 , BT#681, lanes 16 ± 18). Although interpretation of these observations is complicated by the fact that only a relatively small percentage of PyV LT is complexed with CUTL1, these observations suggest that the formation of the PyV LT/CUTL1 complexes does not grossly interfere with ability of the CUTL1 protein to recognize its cognate binding site.
Discussion
In eort to assess the importance of inactivation of the Rb family members in mammary tumorigenesis, we have derived transgenic mice which express the PyV LT antigen in mammary epithelium. Although mammary epithelial speci®c expression of PyV LT lead to the development of mammary tumors in these mice, both the low penetrance of the tumor phenotype and the focal nature of the tumors suggest that expression of PyV LT is not sucient for the induction of mammary tumors. The induction of mammary tumors was further correlated with the formation of speci®c complexes of PyV LT antigen and members of the Rb family. Interestingly, in addition to the occurrence of mammary tumor, the PyV LT transgenic strains frequently develop uterine leiomyoma and testicular tumors. The induction of both the uterine and mammary tumors by PyV LT antigen was further correlated with its capacity to associate with the murine CUTL1 homeodomain protein. These observations suggest that PyV LT can induce both mammary and uterine tumors by complexing with both Rb family and CUTL1 growth regulators. Two lines of evidence suggest that mammary glandspeci®c expression of PyLT antigen is not sucient for 
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CUT CUT CUT --6.14 6.14 IP ANTIBODY PyV LT CUT Figure 5 The murine CUTL1 protein is complexed with PyV LT in both mammary tumors and uterine leiomyomas. Immunoprecipitation of protein lysates with either CUTL1 speci®c antibodies (CUT, lanes 1, 4, 5), nonspeci®c Neu antibodies (6.14) (lanes 3, 7), beads alone (lanes 2, 6). These immunoprecipitates were subjected to immunoblot analyses with PyV LT speci®c antisera (LT, upper panel) or CUTL1 antisera (CUT) (lower panel) Sinn et al., 1987) . Given the latency and the clonal nature of tumors arising from these transgenic models, these observations suggest that additional genetic lesions are necessary for tumorigenesis. In addition to the PyV LT antigen-induced mammary tumors, expression of PyV LT in other tissues also results in the induction of tumors. In particular, expression of PyV LT antigen in the reproductive tracts of both males and females resulted in the development of testicular and leiomyoma tumors respectively. These observations are consistent with previous studies with transgenic mice expressing either PyV or SV40 LT antigens in the reproductive tracts (Chalifour et al., 1992; PaquisFlucklinger et al., 1993; Romagnolo et al., 1996) . In both sets of transgenic strains ectopic expression of these papovaviral LT antigens resulted in the induction of either testicular or leiomyoma tumors. In contrast, transgenic mice carrying the entire PyV early region fail to develop comparable tumor phenotypes despite the high expression of PyV LT in the reproductive tract (Wang and Bautch, 1991) . One possible explanation for this discrepancy is that these transgenic strains frequently develop haemaginomas which results in death before these reproductive tract tumors can develop.
The induction of mammary tumors in these PyV LT antigen strains was closely associated with the capacity of this PyV LT to associate with members of the Rb family including Rb, p107, and p130 (Figure 4) . The ability of PyV LT to bind and functionally inactivate Rb family members likely contributes to observed tissue speci®c transforming properties of PyV LT antigen. Indeed, PyV LT antigen mutants which fail to bind Rb, also fail to cooperatively transform ®broblasts in focus forming assays (Pilon et al., 1996) . Consistent with the importance of the role of the Rb family in the induction of these phenotypes, we have observed that the levels of PyV LT protein are elevated in tumor tissue compared to adjacent normal tissue (Figure 3) . The elevated levels of PyV LT observed during mammary tumor progression in the strains may re¯ect a selection for complete sequestration of the endogenous Rb family members in the mammary epithelial cell. Ultimately, the association of Rb with PyV LT may eect Rb associated E2F transcriptional activity. Interestingly, homozygous deletion of E2F-1 in mice does not interfere with normal development. However, these animals are predisposed to a broad range of malignancies including uterine sarcomas, lung adenocarcinomas, and lymphomas (Yamasaki et al., 1996) . In this regard, it is noteworthy that the uterine dysplasia observed in the E2F-1 de®cient mice resemble the uterine lesion in the PyV LT strains suggesting that PyV LT may also be eecting E2F-1 function through its interaction with the Rb family (Yamasaki et al., 1996) . Although these observations suggest that the observed phenotypes may in part be due to the ability of PyV LT to bind and functionally inactivate members of the Rb family, our observations suggest Figure 7 Formation of CUTL1/PyV LT complexes does not eect the ability of CUTL1 to recognize its cognate binding site. Electrophoretic mobility shift assays (EMSA) were performed using total protein extracts from normal and tumor tissues as indicated. Total extracts (20 mg of protein) were incubated 15 min at room temperature with radiolabeled oligonucleotides encoding a CUTL1 consensus binding site in the absence (No Ab) or presence of monoclonal antibodies directed against either CUTL1 (antiCut) or hemaglutinin (anti-HA). Protein DNA complexes were resolved on a nondenaturing gel that the transforming activity of PyV LT may also correlate with its ability to complex with murine CUTL1 homeobox gene product ( Figure 5 and 6). The murine CUTL1 was initially identi®ed as a transcriptional repressor of the c-myc proto-oncogene . Given the known transforming potential of c-myc in the mammary epithelium of transgenic mice , it is conceivable that interaction of PyV LT with CUTL1 may in¯uence tumor formation by aecting the levels of c-myc transcription. However, RNase protection analyses of tumor RNA samples from either leiomyoma or mammary tumor samples showed only a weak 1.5 ± 2-fold induction of myc transcripts compared to normal control tissue RNA samples (unpublished observations). Although, activation of c-myc may not be the primary mechanism by which the CUTL1/PyV LT complex functions, formation of this complex may aect the ability of CUTL1 to modulate transcription of other downstream genes. Indeed, CUTL1 is known to negatively regulate the transcription gp91-phox and Ncam genes (Valarche et al., 1993; Skalnik et al., 1991) .
Further support for a negative role for CUTL1 in tumor progression stems from the recent observation that a large proportion of leiomyomas possess cytogenetic deletion of the chromosomal region spanning the human CUTL1 gene (Zeng et al., 1997; Lemieux et al., 1994) . In addition, it has recently found that 9/70 human primary breast cancers possess deletions which map to the human CUTL1 gene (A Nepveu, personal communication) . It is tempting to speculate that the complex formed between PyV LT and the CUTL1 results in the inactivation of one of the growth suppressor activity of CUTL1 which leads to tumor formation. Another interesting feature of the PyV LT/CUTL1 interaction is the formation of this complex also appears to be associated with increased steady state levels of CUTL1 protein (Figures 5 and 6) . Indeed, interaction of SV40 LT with the p53 tumor suppressor gene product also results in stabilization of p53 protein levels (Reich et al., 1983) . In this regard, it is interesting to note that SV40 LT antigen also appears to form speci®c complexes with the CUTL1 complex (A Nepveu, personal communication). Indeed, uterine speci®c expression of SV40 LT antigen in transgenic mice also results in the induction of leiomyomas (Romagnolo et al., 1996) . In addition, we have also provided evidence that the formation of these CUTL1/PyV LT complexes may be restricted to certain tissue sites. Although we can detect complexes of PyV LT and CUTL1 in the mammary and uterine tissues, we have failed to detect comparable complexes in the testicular tissues (Figure 6 ). Consistent with these analyses, we have also failed to detect elevated levels of CUTL1 protein in these testicular tumors. These observations argue that certain tissue speci®c factors may be required to modulate the interaction of CUTL1 and PyV LT antigen.
Whereas these studies suggest that the formation of these CUTL1/LT antigen complexes may be involved in both mammary and uterine growth disorders, the mechanism by which PyV LT in¯uences the biological activity of CUTL1 is unclear. We have demonstrated that the binding properties of CUTL1 in vitro are not signi®cantly aected (Figure 7) . However, it is conceivable, that formation of CUTL1/PyV LT complexes may alter the transcriptional speci®city of CUTL1. Future studies directed towards elucidating the biological signi®cance of the CUTL1/PyV LT complexes may provide important insight into the molecular basis for tumor induction in these strains.
Materials and methods
DNA constructions
To construct the MMTV/LTN expression plasmid, PyV LT cDNA (a generous gift of Dr J Hassell) was excised with BamHI and BglII and the recessed ends blunted with Klenow fragment of DNA polymerase I. BclI linkers were then ligated to the blunt ends and ligated into a unique BclI site engineered in the EcoRI site of the MMTV expression cassette 206 (Guy et al., 1992) .
The PyV MT-antigen and PGK-1 ribonucleotide protection probes (riboprobe) pSP65mT (MTR) were generous gifts from Dr M Rudnicki and Dr J Hassell (Guy et al., 1992) . The SV40 polyadenylation-speci®c riboprobe (SPA) contains the SV40 polyadenylation signals (SV40 nucleotides 2536 ± 2773/4103 ± 4713) into the BamHI and HindIII sites of Bluescript KS (Stratagene). After cleavage of MTR and SPA with HindIII, PGK-1 with EcoNI and MTsn301 with XbaI, the antisense riboprobes were generated in vitro as described previously (Melton et al., 1984) . All oligonucleotide synthesis and automated DNA sequencing were performed by Dinsdale Gooden and Brian Allore of the MOBIX Main Central Facility, McMaster University.
Generation and identi®cation of transgenic mice
DNA was prepared for microinjection by digestion with 4 U/mg of SalI and SpeI for 1.5 h. The DNA was electrophoresed through a 1% agarose gel and puri®ed as described previously (Sinn et al., 1987) . Superovoluated FVB/N female mice (Taconic Farms, Germantown, Pa) were mated with FVB/N males the night before injection. After isolation of the fertilized one-cell mouse embryos, the pronuclei of these zygotes were injected with 0.5 ± 1 pl of DNA solution (5 mg/ml). Following microinjection, viable eggs were transferred to the oviducts of pseudo-pregnant Swiss-Webster mice (Taconic Farms).
To identify transgenic progeny, genomic DNA was extracted from 1.5 cm tail clippings as described by Muller et al. (1988) . The nucleic acid pellet was resuspended in 100 ml of distilled water at approximately 1 mg/ml and 15 ml of the DNA solution was digested with 30 U of BamHI for 1.5 h. Following gel electrophoresis and Southern blot transfer (Southern, 1975) to Gene-Screen ®lters (Dupont), the ®lters were hybridized with transgene radiolabeled with a-32 P-dCTP (Dupont) by random priming. Radiolabeled probes derived from the PyV LT cDNA were used to identify MMTV/LT transgenic strains.
RNA analysis
RNA was isolated from various tissues by using the Guandinium Isothiocyanate modi®cation of CsC1 sedimentation gradient described by Chirgwin et al. (1979) . Tissue was¯ash frozen in liquid nitrogen and stored at 7808C or immediately homogenized in 3 ml of guanidine isothiocyanate (GIT, BRL) solution (4 M GIT, 25 mM sodium citrate and 0.1 M bmercaptoethanol). The homogenate was layered onto 4 ml of 5.7 M CsCl containing 25 mM sodium acetate (pH 5.2) and RNA pelleted by ultracentrifugation at 32 000 r.p.m. at 208C using an SW41Ti rotor (Beckman) for 24 h. The GIT and CsCl layers were aspirated o and RNA pellet was resuspended in 500 ml of sterile water plus 300 mM sodium acetate (pH 5.2) and precipitated with two volumes of ice cold ethanol. RNA yield was determined by U.V. absorption at 260 nm (1 OD260=40 mg/ml RNA).
RNase protection assays were performed as described by Melton et al. (1984) , using 30 mg of total cellular RNA per tissue (except where noted) incubated with 1 ml of hybridization buer (80% formamide, 40 mM piperazine-N,N'-bis (2-ethanesulfonic acid) (PIPES) pH 6.4, 1 mM EDTA pH 8.0 and 400 mM NaCl) at 858C for 5 min. The hybridization reaction was then allowed to anneal for at least 8 h at 508C and subjected to RNase digestion as described previously (Melton et al., 1984) . Digests were terminated by addition of 20 ± 30 mg RNase-free tRNA and 500 ml phenol:chloroform (1 : 1) followed by ethanol precipitation. RNA pellets were dried for 10 min under vacuum, resuspended in 10 ml of formamide loading buer (80% formamide, 10 mM EDTA pH 8.0, 1 mg/ml xylene cyanol FF, 1 mg/ml bromophenol blue) boiled for 7 min at 958C and resolved in a 6% urea polyacrylamide gel (40% acrylamide: 2% N,N'-methylene-bis-acrylamide, 7 M urea, 0.001% ammonium persulfate and 0.0005% N,N,N'N'-tetramethyl-ethylenediamine (TEMED) electrophoresed at 60 ± 80 amps in 16TBE running buer (0.1 M Tris, 0.08 M boric acid, 0.002 M EDTA pH 8.0). The gel was dried and exposed at 7708C against Kodak XAR-5 ®lm in the presence of intensifying screens.
Protein extract preparation
Tissue samples were¯ash frozen in liquid nitrogen and ground to a ®ne powder with chilled mortar and pestle. Cells were lysed on ice for 30 min in TNE lysis buer (20 mM Tris pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 2.5 mM EDTA, 1 mM sodium orthovanadate, 10 mM sodium¯uoride, 10 mg aprotinin per ml and 10 mg leupeptin per ml) with constant agitation. Lysates were cleared by two consecutive centrifugations at 13 000 g for 5 min each time. Supernatants were removed and their protein concentration determined using the Bradford assay kit (Biorad).
Immunoblot and immunoprecipitation analyses
The rat monoclonal pAb701 speci®c for PyV LT was a generous gift from S. Dilworth. (ICRF London). Both polyclonal and monoclonal antibodies speci®c to the murine CUTL1 were generated by the laboratory of Dr A Nepveu. Unless otherwise speci®ed, a total of 100 mg total protein lysate was used for each sample analysed. An equal volume of 26 protein sample loading buer (62.5 mM Tris pH 6.8, 2% SDS, 10% glycerol, 5% bmercaptoethanol, 0.02% bromophenol blue) was added and mixtures were boiled for 10 min at 958C. Proteins were resolved in SDS-polyacrylamide gels, transferred electrophoretically onto polyvinylidine di¯uoride (PVDF) membranes (Immobilon-P, Millipore). Membranes were incubated overnight in 3% low-fat powdered skim milk in TBS (20 mM pH 7.5, 150 mM NaCl, 5 mM KCl) or 3% BSA (Sigma) in TBS for anti-phosphotyrosine immunoblots. Membranes were subsequently incubated for 2 h at room temperature with antibodies (1 : 1000 for all monoclonal antibody preparations and 1 : 250 for all polyclonal antibody preparations). After washing four times (10 min each time) in TBS plus 0.01% Tween 20 (TBST), membranes were incubated for 1 h at room temperature with the appropriate secondary antibody conjugated to horseradish peroxidase (HRP, Biocan Scienti®c) at 1 : 2500 dilution. The membranes were washed four more times in TBS and proteins were detected using the enhanced chemiluminescence detection system (ECL, Amersham).
Immunoprecipitations were performed by preincubating antigen-speci®c antibody (1 ± 2 mg monoclonal; 5 ± 10 mg polyclonal) with 30 ± 40 ml of Protein G Sepharose fast¯ow (Pharmacia) in 800 ml 16PBS (140 mM NaCl; 2.7 mM KCl; 4.3 mM Na 2 HPO 4 ; 1.4 mM KH 2 PO 4 ) for 2 ± 12 h at 48C on a rotating platform. Antibody-bound beads were washed once with 1 ml PBS and once 1 ml lysis buer. 500 mg to 1 mg of total protein lysate was added to a total volume of 700 ml and incubated with the pre-bound beads for 1 ± 5 h at 48C on a rotating platform. Beads were subsequently washed ®ve times in lysis buer following which bound antigen could subsequently be analysed.
Electrophoretic mobility shift assays (EMSA)
Total protein extracts were preincubated for 5 min at room temperature in 25 mM NaCl, 10 mM Tris pH 7.5, 1 mM MgCl 2 , 5 mM EDTA pH 8.0, 5% glycerol and 1 mM DTT with 5 mg of PCR-ampli®ed random oligonucleotide as a non speci®c competitor. A double-stranded nucleotide containing the Cut-consensus binding site (upper strand: 5'-AAAAGAAGCTTATCGATACCGT-3') was end-labeled using the Klenow fragment of DNA polymerase and 10 pg of the probe (20 000 c.p.m.) was then incubated with the protein mixture for 15 min. Samples were loaded on a 5% polyacrylamide gel (30 : 1) and separated by electrophoresis at 8 volts/cm for 2 h in 50 mM Tris-0.38 M glycine-1 mM EDTA (pH 8.5). Gels were then dried and visualized by autoradiography.
Histological evaluation
Complete autopsies were performed and both gross and microscopic examinations were done. Tissues were ®xed in 4% paraformaldehyde, blocked in paran, sectioned at 5 mm, stained with hematoxylin and eosin, and examined.
